Cargando…
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
BACKGROUND: The efficacy and safety of rituximab (RTX) in adult frequent-relapsing (FR) or steroid-dependent (SD) nephrotic syndrome (NS), including minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), are still inconclusive. METHODS: We performed a systematic review and meta-a...
Autores principales: | Xue, Cheng, Yang, Bo, Xu, Jing, Zhou, Chenchen, Zhang, Liming, Gao, Xiang, Dai, Bing, Yu, Shengqiang, Mao, Zhiguo, Mei, Changlin, Xu, Chenggang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173623/ https://www.ncbi.nlm.nih.gov/pubmed/34094516 http://dx.doi.org/10.1093/ckj/sfaa191 |
Ejemplares similares
-
Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020) -
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
por: Ren, Hong, et al.
Publicado: (2017) -
Rituximab treatment of adults with primary focal segmental glomerulosclerosis
por: Wang, Liuwei, et al.
Publicado: (2023) -
Focal Segmental Glomerulosclerosis: Assessing the Risk of Relapse
por: Troyanov, Stéphan, et al.
Publicado: (2023) -
Rituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2022)